Practitioners should document supplement use in subjects receiving therapy for cancer.
To date, MSCs have been tested for a variety of indications in more than 2,000 human subjects as therapy for a variety of diseases due to their low immunogenicity, immunomodulatory effects, and ability to secrete endothelial and epithelial growth factors.
Subjects failing therapy at any time during the study received rescue medication immediately and were followed until Day 42 or resolution.
Serious adverse events in subjects on therapy were few and reported previously [ 24].
For some subjects the therapy was very successful, whereas in others it was not.
Subjects received therapy as an in-patient in the TCM unit at the Fudan University Shanghai Cancer Center.
Subjects on therapy with β-blockers, smokers, or those unable to perform the programs were also excluded.
In these subjects antifungal therapy can likely be withheld safely because a low score essentially rules out candidemia.
Infusion site pain was the most common (82%) adverse drug event (ADE) reported, but only 4.9% of subjects discontinued therapy.
All subjects initiated therapy with regimens containing either ZDV or ddI, and although use of only one of these agents was preferred, use of both was allowed.
